title: [Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series].
abstract: BACKGROUND
  Retinopathy of prematurity (ROP) is an eye disease caused by an alteration in retinal vasculogenesis that may lead to partial or complete vision loss with a harmful impact in terms of neurodevelopment. The purpose of the present study was to determine the neurodevelopment in patients with type i retinopathy of prematurity treated with intravitreal bevacizumab.
  
  
  METHODS
  Case series. The inclusion criteria were: patients with type I ROP treated with a dose of 0.625mg/0.025ml of intravitreal bevacizumab. Demographic data and comorbidities were documented. Neurodevelopment was evaluated with the screening test of the Bayley Scale of Infant Development (BSID) in all patients between 11 and 28 weeks of age.
  
  
  RESULTS
  Seven patients were included in the study. Four patients showed normal neurodevelopment according to the overall scores of the BSID scale. The distribution of high risk for neurodevelopmental delay in the different areas evaluated were as follows: 3 patients presented it in the cognitive area, one in the receptive communication area, one in the expressive area, one in the fine motor skills and 3 patients in the gross motor skills area.
  
  
  CONCLUSIONS
  In these case series, the majority of patients treated with intravitreal bevacizumab for ROP showed normal neurodevelopment scores.
authors.affiliation: Unidad de Medicina Familiar Número 80, IMSS, Morelia, Michoacán, México.
authors.forename: Sarah Melania
authors.initials: SM
authors.lastname: Martínez-García
authors.affiliation: Servicio de Retina, Unidad Oftalmológica, Clínica David, Morelia, Michoacán, México. Electronic address: tolodamota@yahoo.com.mx.
authors.forename: Sergio Eustolio
authors.initials: SE
authors.lastname: Hernández-Da Mota
authors.affiliation: Hospital General Regional Número 1, IMSS, Morelia, Michoacán, México.
authors.forename: Araceli
authors.initials: A
authors.lastname: Rubio-Rangel
authors.affiliation: Hospital General Regional Número 1, IMSS, Morelia, Michoacán, México.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Rojas-Flores
authors.affiliation: Unidad de Medicina Familiar Número 80, IMSS, Morelia, Michoacán, México.
authors.forename: Mayra Edith
authors.initials: ME
authors.lastname: Vieyra-López
authors.affiliation: Servicio de Retina, Hospital Dr. Luis Sánchez Bulnes, Asociación para Evitar la Ceguera en México, Ciudad de México, México.
authors.forename: María Ana
authors.initials: MA
authors.lastname: Martínez-Castellanos
authors.affiliation: Servicio de Retina, Unidad Oftalmológica, Clínica David, Morelia, Michoacán, México.
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Zavala-Martínez
authors.affiliation: Unidad de Medicina Familiar Número 80, IMSS, Morelia, Michoacán, México.
authors.forename: Anel
authors.initials: A
authors.lastname: Gómez García
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002585:Cesarean Section; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D006932:Hyperbilirubinemia / Q000150:complications; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D058449:Intravitreal Injections; D008297:Male; D008423:Maternal Age; D065886:Neurodevelopmental Disorders / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology; D012178:Retinopathy of Prematurity / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Bevacizumab; Factor de crecimiento vascular endotelial; Retinopathy of prematurity; Retinopatía del prematuro; Vascular endothelial growth factor